abortion pill cme

abortion pill cme

medication abortion cme

medication abortion cme

This one-hour interactive training uses video learning to present an evidence-based approach to evaluating and counseling patients seeking early abortion or miscarriage management.

This one-hour interactive training uses video learning to present an evidence-based approach to evaluating and counseling patients seeking early abortion or miscarriage management.

Get CME Credit

Get CME Credit

Get CME Credit

Get CME Credit

Start SELF-PACED Learning

Start SELF-PACED Learning

Start SELF-PACED Learning

Start SELF-PACED Learning

This CME was brought to you by the following partners.

This CME was brought to you by the following partners.

1 in every 4 u.s. women has an abortion,
and many have had a miscarriage.

1 in every 4 u.s. women has an abortion,
and many have had a miscarriage.

overview

overview

In a growing number of communities, women need to travel considerable distances to obtain clinical assistance with an abortion or miscarriage. Such travel is a particular burden for rural and low-income women. Both early abortion and miscarriage can be managed with a single dose of oral Mifepristone followed by Misoprostol.

In a growing number of communities, women need to travel considerable distances to obtain clinical assistance with an abortion or miscarriage. Such travel is a particular burden for rural and low-income women. Both early abortion and miscarriage can be managed with a single dose of oral Mifepristone followed by Misoprostol.

Access our 1-hour, video-based, medication abortion training for free — or pay to earn CME credits.

Access our 1-hour, video-based, medication abortion training for free — or pay to earn CME credits.

Designed for all primary care prescribing clinicians.

Designed for all primary care prescribing clinicians.

Self-paced interaction with videos, key questions, and review of resources.

Self-paced interaction with videos, key questions, and review of resources.

Providers can earn 1.0 credit hours toward CME and CE requirements.

Providers can earn 1.0 credit hours toward CME and CE requirements.

about medication abortion

about medication abortion

Licensed physicians — and, in twenty states, advanced practice clinicians — can provide Mifepristone. Most patients who received abortions from primary care providers are very satisfied with the experience, and most general medicine patients felt their clinic should provide medication abortion.

Licensed physicians — and, in twenty states, advanced practice clinicians — can provide Mifepristone. Most patients who received abortions from primary care providers are very satisfied with the experience, and most general medicine patients felt their clinic should provide medication abortion.

Download Overview

Download Overview

Download Overview

Download Overview

learning goals

learning goals

This one-hour interactive training presents an evidence-based approach to evaluating and counseling patients seeking early abortion or miscarriage management. It is designed to increase primary care providers' ability to counsel patients on how to use Mifepristone to terminate an early pregnancy.

This one-hour interactive training presents an evidence-based approach to evaluating and counseling patients seeking early abortion or miscarriage management. It is designed to increase primary care providers' ability to counsel patients on how to use Mifepristone to terminate an early pregnancy.

Identifying patients who can safely use Mifepristone.

Identifying patients who can safely use Mifepristone.

Counseling patients how to take the medications.

Counseling patients how to take the medications.

Evaluating patients with possible side-effects.

Evaluating patients with possible side-effects.

Requirements

Requirements

An Internet connection, up-to-date web browser, Adobe Acrobat Reader ❋, and video streaming capability are required to participate in this course.

❋ Required only to view printable (PDF) materials.

An Internet connection, up-to-date web browser, Adobe Acrobat Reader ❋, and video streaming capability are required to participate in this course.

❋ Required only to view printable (PDF) materials.

WHICH LEARNING PATH SHOULD YOU CHOOSE?

WHICH LEARNING PATH SHOULD YOU CHOOSE?

Both pathways provide the same content to eager learners. One is CME-Accredited ($60) and one is Self-Paced (Free).

Both pathways provide the same content to eager learners. One is CME-Accredited ($60) and one is Self-Paced (Free).

CME-Accredited

CME-Accredited

Providers can earn 1.0 credit hours toward CME and CE requirements.

Providers can earn 1.0 credit hours toward CME and CE requirements.

60

Get CME Credit

Get CME Credit

Get CME Credit

Get CME Credit

Self-paced interaction

Self-paced interaction

3 short videos, 25 key questions, and review of web-based resources provide all the training required. No CME credit is provided for this.

3 short videos, 25 key questions, and review of web-based resources provide all the training required. No CME credit is provided for this.

Start Learning

Start Learning

Start Learning

Start Learning

Disclosures & Acknowledgements

It is the policy of the University of California Schools of Medicine to ensure balance, independence, objectivity and scientific rigor. All persons involved in the selection, development and presentation of content are required to disclose any real or apparent conflicts of interest.

Disclosures: None of the following faculty, project staff or reviewers have any financial relationships with commercial interests relevant to the content of this activity.

Funding: Society of Family Planning Research Fund

Faculty:

  • Eleanor Bimla Schwarz, MD, MS, Course Director Professor of Medicine, University of California, Davis

  • Mindy Sobota, MD, MS, MPhil Associate Professor of Medicine, Clinician Educator, Brown University

  • Suzan Goodman, MD, MPH Associate Clinical Professor of Family and Community Medicine, UCSF; TEACH Program Curriculum Director; UCSF Bixby Center for Global Reproductive Health

Clinical Reviewers:

  • Jessica Beaman, MD, MPH, Assistant Professor of Medicine, UC San Francisco

  • Courtney Benedict, CNM, MSN, Associate Director Medical Standards Implementation
    Planned Parenthood Federation of America

  • Rachel S. Casas, MD, EdM, Assistant Professor of Medicine; Penn State College of Medicine

  • Cynthia H. Chuang, MD, MSc, Chief, Division of General Internal Medicine
    Professor of Medicine and Public Health Sciences, Penn State College of Medicine

  • Daniel Grossman, MD, Professor, Department of Obstetrics, Gynecology & Reproductive Sciences; Director, Advancing New Standards in Reproductive Health (ANSIRH), UC San Francisco

  • Ivonne McLean, MD, Faculty Attending, Community Family Health Center, New York; Reproductive Health Access Project (RHAP) Provider

  • Christine Prifti, MD, Instructor of Medicine, Boston University School of Medicine

Web Development: Nitid Bit, LLC

Video Producer/Editor: Luke Walden

Director of Photography: Charlotte Hornsby

Sound Recordist: Alistair Farrant

Acting: Julia Register

Off-Label Disclosure: This educational activity contains discussion of unlabeled uses of agents that are not approved by the FDA. Please consult the prescribing information for each product.

Cultural Competency: This activity complies with California Assembly Bill 1195 which requires CME courses with patient care components to include curriculum addressing cultural and linguistic competencies.
The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views of the University of California, Brown University, or the Society of Family Planning.

References:

  1. Abbas D, et al. Outpatient medical abortion is safe and effective through 70 days gestation. Contraception. 2015. PMID: 26118638

  2. Achilles SL, et al. Prevention of infection after induced abortion: SFP guideline 20102. Society of Family Planning. Contraception. 2011. PMID: 21397086

  3. Aldrich T, et al. Does methotrexate confer a significant advantage over misoprostol alone for early medical abortion? A retrospective analysis of 8678 abortions. BJOG. 2007. PMID: 17439563

  4. Bearak JM, et al. Disparities and change over time in distance women would need to travel to have an abortion in the USA: a spatial analysis. Lancet Public Health. 2017. PMID: 29253373

  5. Chen AY, et al. Bleeding after medication-induced termination of pregnancy with two dosing schedules of mifepristone and misoprostol. Contraception. 2006 PMID:16531178

  6. Chen MJ, et al. Mifepristone With Buccal Misoprostol for Medical Abortion: A Systematic Review. Obstet Gynecol 2015. PMID: 26241251 https://escholarship.org/uc/item/0v4749ss

  7. Cleland K, et al. Significant adverse events and outcomes after medical abortion. Obstet Gynecol. 2013. PMID:23262942

  8. Coelho KE, et al. Misoprostol embryotoxicity: clinical evaluation of fifteen patients with arthrogryposis. Am J Med Genet. 2000. PMID: 11186880D

  9. Dabash R, et al. A double-blind randomized controlled trial of mifepristone or placebo before buccal misoprostol for abortion at 14-21 weeks of pregnancy. Int J Gynaecol Obstet 2015. PMID: 25896965

  10. Davis A, et al. Bleeding patterns after early abortion with mifepristone and misoprostol or manual vacuum aspiration. Am Med Womens Assoc 2000.

  11. Dickinson JE, et al. Mifepristone and oral, vaginal, or sublingual misoprostol for second-trimester abortion: a randomized controlled trial. Obstet Gynecol 2014. PMID: 24807339

  12. Fiala C, et al. Verifying the effectiveness of medical abortion; ultrasound versus hCG testing. Eur J Obstet Gynecol Reprod Biol. 2003. PMID: 12860340

  13. Fjerstad M, et al. Rates of serious infection after changes in regimens for medical abortion. NEJM. 2009. PMID: 19587339

  14. Friedlander EB, et al. Prophylactic Pregabalin to Decrease Pain During Medication Abortion: A Randomized Controlled Trial. Obstet Gynecol. 2018. PMID: 30095762

  15. Gatter M, et al. Efficacy and safety of medical abortion using mifepristone and buccal misoprostol through 63 days. Contraception. 2015. PMID: 25592080

  16. Guttmacher Institute, An Overview of Abortion Laws May 2019 https://www.guttmacher.org/state-policy/explore/overview-abortion-laws

  17. Guttmacher Institute, Report on State Abortion Policy https://www.guttmacher.org/gpr/2019/05/improving-access-abortion-telehealth

  18. Hollenbach SJ, et al. “Provoked” feto-maternal hemorrhage may represent insensible cell exchange in pregnancies from 6 to 22 weeks gestational age” Contraception. 2019. https://www.contraceptionjournal.org/article/S0010-7824(19)30129-5/fulltext

  19. Guest J, et al. Randomized controlled trial comparing the efficacy of same-day administration of mifepristone and misoprostol for termination of pregnancy with the standard 36 to 48-hour protocol. BJOG. 2007. PMID: 17305893K

  20. Kapp N, et al. Medical abortion in the late first trimester: a systematic review. Contraception 2019. PMID: 30444970

  21. Livshits A, et al. Ibuprofen and paracetamol for pain relief during medical abortion: A double-blind randomized controlled study. Fertility and sterility. 2009. PMID:18359021

  22. Mark A, et al. Foregoing Rh testing and anti-D immunoglobulin for women presenting for early abortion: a recommendation from NAF’s Clinical Policies Committee. Contraception 2019. PMID: 30867121

  23. National Abortion Federation, Clinical Practice Guidelines https://prochoice.org/resources/clinical-policy-guidelines/

  24. Sheldon WR et al. Early abortion with buccal versus sublingual misoprostol alone: a multicenter, randomized trial. Contraception 2019 PMID:30831103

  25. Raymond EG, et al. Prophylactic compared with therapeutic ibuprofen analgesia in first-trimester medical abortion: a randomized controlled trial. Obstet Gynecol. 2013. PMID:23921857.

  26. Raymond EG, et al. Sixteen Years of Overregulation: Time to Unburden Mifeprex. Mifeprex REMS Study Group. NEJM 2017. PMID: 28225670

  27. Raymond EG, et al. Serial multilevel urine pregnancy testing to assess medical abortion outcome: a meta-analysis. Contraception. 2017. PMID: 28041991

  28. Raymond EG, et al. Simplified medical abortion screening: a demonstration project. Contraception 2018. PMID: 29170088

  29. Raymond EG, et al. Efficacy of Misoprostol Alone for First-Trimester Medical Abortion: A Systematic Review. Obstet Gynecol 2019. PMID: 3053156

  30. Schreiber CA, et al. Mifepristone Pretreatment for the Medical Management of Early Pregnancy Loss. NEJM. 2018. PMID: 29874535

  31. Society of Family Planning Clinical Guideline. Medical management of first-trimester abortion. Contraception 2014. http://goo.gl/BJiETT

  32. Society of Family Planning Clinical Guidelines https://www.societyfp.org/resources/clinical-guidelines

  33. Upadhyay UD, et al. Incidence of emergency department visits and complications after abortion. Obstet Gynecol 2015. PMID: 25560122

Disclosures & Acknowledgements

It is the policy of the University of California Schools of Medicine to ensure balance, independence, objectivity and scientific rigor. All persons involved in the selection, development and presentation of content are required to disclose any real or apparent conflicts of interest.

Disclosures: None of the following faculty, project staff or reviewers have any financial relationships with commercial interests relevant to the content of this activity.

Funding: Society of Family Planning Research Fund

Faculty:

  • Eleanor Bimla Schwarz, MD, MS, Course Director Professor of Medicine, University of California, Davis

  • Mindy Sobota, MD, MS, MPhil Associate Professor of Medicine, Clinician Educator, Brown University

  • Suzan Goodman, MD, MPH Associate Clinical Professor of Family and Community Medicine, UCSF; TEACH Program Curriculum Director; UCSF Bixby Center for Global Reproductive Health

Clinical Reviewers:

  • Jessica Beaman, MD, MPH, Assistant Professor of Medicine, UC San Francisco

  • Courtney Benedict, CNM, MSN, Associate Director Medical Standards Implementation
    Planned Parenthood Federation of America

  • Rachel S. Casas, MD, EdM, Assistant Professor of Medicine; Penn State College of Medicine

  • Cynthia H. Chuang, MD, MSc, Chief, Division of General Internal Medicine
    Professor of Medicine and Public Health Sciences, Penn State College of Medicine

  • Daniel Grossman, MD, Professor, Department of Obstetrics, Gynecology & Reproductive Sciences; Director, Advancing New Standards in Reproductive Health (ANSIRH), UC San Francisco

  • Ivonne McLean, MD, Faculty Attending, Community Family Health Center, New York; Reproductive Health Access Project (RHAP) Provider

  • Christine Prifti, MD, Instructor of Medicine, Boston University School of Medicine

Web Development: Nitid Bit, LLC

Video Producer/Editor: Luke Walden

Director of Photography: Charlotte Hornsby

Sound Recordist: Alistair Farrant

Acting: Julia Register

Off-Label Disclosure: This educational activity contains discussion of unlabeled uses of agents that are not approved by the FDA. Please consult the prescribing information for each product.

Cultural Competency: This activity complies with California Assembly Bill 1195 which requires CME courses with patient care components to include curriculum addressing cultural and linguistic competencies.
The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views of the University of California, Brown University, or the Society of Family Planning.

References:

  1. Abbas D, et al. Outpatient medical abortion is safe and effective through 70 days gestation. Contraception. 2015. PMID: 26118638

  2. Achilles SL, et al. Prevention of infection after induced abortion: SFP guideline 20102. Society of Family Planning. Contraception. 2011. PMID: 21397086

  3. Aldrich T, et al. Does methotrexate confer a significant advantage over misoprostol alone for early medical abortion? A retrospective analysis of 8678 abortions. BJOG. 2007. PMID: 17439563

  4. Bearak JM, et al. Disparities and change over time in distance women would need to travel to have an abortion in the USA: a spatial analysis. Lancet Public Health. 2017. PMID: 29253373

  5. Chen AY, et al. Bleeding after medication-induced termination of pregnancy with two dosing schedules of mifepristone and misoprostol. Contraception. 2006 PMID:16531178

  6. Chen MJ, et al. Mifepristone With Buccal Misoprostol for Medical Abortion: A Systematic Review. Obstet Gynecol 2015. PMID: 26241251 https://escholarship.org/uc/item/0v4749ss

  7. Cleland K, et al. Significant adverse events and outcomes after medical abortion. Obstet Gynecol. 2013. PMID:23262942

  8. Coelho KE, et al. Misoprostol embryotoxicity: clinical evaluation of fifteen patients with arthrogryposis. Am J Med Genet. 2000. PMID: 11186880D

  9. Dabash R, et al. A double-blind randomized controlled trial of mifepristone or placebo before buccal misoprostol for abortion at 14-21 weeks of pregnancy. Int J Gynaecol Obstet 2015. PMID: 25896965

  10. Davis A, et al. Bleeding patterns after early abortion with mifepristone and misoprostol or manual vacuum aspiration. Am Med Womens Assoc 2000.

  11. Dickinson JE, et al. Mifepristone and oral, vaginal, or sublingual misoprostol for second-trimester abortion: a randomized controlled trial. Obstet Gynecol 2014. PMID: 24807339

  12. Fiala C, et al. Verifying the effectiveness of medical abortion; ultrasound versus hCG testing. Eur J Obstet Gynecol Reprod Biol. 2003. PMID: 12860340

  13. Fjerstad M, et al. Rates of serious infection after changes in regimens for medical abortion. NEJM. 2009. PMID: 19587339

  14. Friedlander EB, et al. Prophylactic Pregabalin to Decrease Pain During Medication Abortion: A Randomized Controlled Trial. Obstet Gynecol. 2018. PMID: 30095762

  15. Gatter M, et al. Efficacy and safety of medical abortion using mifepristone and buccal misoprostol through 63 days. Contraception. 2015. PMID: 25592080

  16. Guttmacher Institute, An Overview of Abortion Laws May 2019 https://www.guttmacher.org/state-policy/explore/overview-abortion-laws

  17. Guttmacher Institute, Report on State Abortion Policy https://www.guttmacher.org/gpr/2019/05/improving-access-abortion-telehealth

  18. Hollenbach SJ, et al. “Provoked” feto-maternal hemorrhage may represent insensible cell exchange in pregnancies from 6 to 22 weeks gestational age” Contraception. 2019. https://www.contraceptionjournal.org/article/S0010-7824(19)30129-5/fulltext

  19. Guest J, et al. Randomized controlled trial comparing the efficacy of same-day administration of mifepristone and misoprostol for termination of pregnancy with the standard 36 to 48-hour protocol. BJOG. 2007. PMID: 17305893K

  20. Kapp N, et al. Medical abortion in the late first trimester: a systematic review. Contraception 2019. PMID: 30444970

  21. Livshits A, et al. Ibuprofen and paracetamol for pain relief during medical abortion: A double-blind randomized controlled study. Fertility and sterility. 2009. PMID:18359021

  22. Mark A, et al. Foregoing Rh testing and anti-D immunoglobulin for women presenting for early abortion: a recommendation from NAF’s Clinical Policies Committee. Contraception 2019. PMID: 30867121

  23. National Abortion Federation, Clinical Practice Guidelines https://prochoice.org/resources/clinical-policy-guidelines/

  24. Sheldon WR et al. Early abortion with buccal versus sublingual misoprostol alone: a multicenter, randomized trial. Contraception 2019 PMID:30831103

  25. Raymond EG, et al. Prophylactic compared with therapeutic ibuprofen analgesia in first-trimester medical abortion: a randomized controlled trial. Obstet Gynecol. 2013. PMID:23921857.

  26. Raymond EG, et al. Sixteen Years of Overregulation: Time to Unburden Mifeprex. Mifeprex REMS Study Group. NEJM 2017. PMID: 28225670

  27. Raymond EG, et al. Serial multilevel urine pregnancy testing to assess medical abortion outcome: a meta-analysis. Contraception. 2017. PMID: 28041991

  28. Raymond EG, et al. Simplified medical abortion screening: a demonstration project. Contraception 2018. PMID: 29170088

  29. Raymond EG, et al. Efficacy of Misoprostol Alone for First-Trimester Medical Abortion: A Systematic Review. Obstet Gynecol 2019. PMID: 3053156

  30. Schreiber CA, et al. Mifepristone Pretreatment for the Medical Management of Early Pregnancy Loss. NEJM. 2018. PMID: 29874535

  31. Society of Family Planning Clinical Guideline. Medical management of first-trimester abortion. Contraception 2014. http://goo.gl/BJiETT

  32. Society of Family Planning Clinical Guidelines https://www.societyfp.org/resources/clinical-guidelines

  33. Upadhyay UD, et al. Incidence of emergency department visits and complications after abortion. Obstet Gynecol 2015. PMID: 25560122

Disclosures & Acknowledgements

It is the policy of the University of California Schools of Medicine to ensure balance, independence, objectivity and scientific rigor. All persons involved in the selection, development and presentation of content are required to disclose any real or apparent conflicts of interest.

Disclosures: None of the following faculty, project staff or reviewers have any financial relationships with commercial interests relevant to the content of this activity.

Funding: Society of Family Planning Research Fund

Faculty:

  • Eleanor Bimla Schwarz, MD, MS, Course Director Professor of Medicine, University of California, Davis

  • Mindy Sobota, MD, MS, MPhil Associate Professor of Medicine, Clinician Educator, Brown University

  • Suzan Goodman, MD, MPH Associate Clinical Professor of Family and Community Medicine, UCSF; TEACH Program Curriculum Director; UCSF Bixby Center for Global Reproductive Health

Clinical Reviewers:

  • Jessica Beaman, MD, MPH, Assistant Professor of Medicine, UC San Francisco

  • Courtney Benedict, CNM, MSN, Associate Director Medical Standards Implementation
    Planned Parenthood Federation of America

  • Rachel S. Casas, MD, EdM, Assistant Professor of Medicine; Penn State College of Medicine

  • Cynthia H. Chuang, MD, MSc, Chief, Division of General Internal Medicine
    Professor of Medicine and Public Health Sciences, Penn State College of Medicine

  • Daniel Grossman, MD, Professor, Department of Obstetrics, Gynecology & Reproductive Sciences; Director, Advancing New Standards in Reproductive Health (ANSIRH), UC San Francisco

  • Ivonne McLean, MD, Faculty Attending, Community Family Health Center, New York; Reproductive Health Access Project (RHAP) Provider

  • Christine Prifti, MD, Instructor of Medicine, Boston University School of Medicine

Web Development: Nitid Bit, LLC

Video Producer/Editor: Luke Walden

Director of Photography: Charlotte Hornsby

Sound Recordist: Alistair Farrant

Acting: Julia Register

Off-Label Disclosure: This educational activity contains discussion of unlabeled uses of agents that are not approved by the FDA. Please consult the prescribing information for each product.

Cultural Competency: This activity complies with California Assembly Bill 1195 which requires CME courses with patient care components to include curriculum addressing cultural and linguistic competencies.
The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views of the University of California, Brown University, or the Society of Family Planning.

References:

  1. Abbas D, et al. Outpatient medical abortion is safe and effective through 70 days gestation. Contraception. 2015. PMID: 26118638

  2. Achilles SL, et al. Prevention of infection after induced abortion: SFP guideline 20102. Society of Family Planning. Contraception. 2011. PMID: 21397086

  3. Aldrich T, et al. Does methotrexate confer a significant advantage over misoprostol alone for early medical abortion? A retrospective analysis of 8678 abortions. BJOG. 2007. PMID: 17439563

  4. Bearak JM, et al. Disparities and change over time in distance women would need to travel to have an abortion in the USA: a spatial analysis. Lancet Public Health. 2017. PMID: 29253373

  5. Chen AY, et al. Bleeding after medication-induced termination of pregnancy with two dosing schedules of mifepristone and misoprostol. Contraception. 2006 PMID:16531178

  6. Chen MJ, et al. Mifepristone With Buccal Misoprostol for Medical Abortion: A Systematic Review. Obstet Gynecol 2015. PMID: 26241251 https://escholarship.org/uc/item/0v4749ss

  7. Cleland K, et al. Significant adverse events and outcomes after medical abortion. Obstet Gynecol. 2013. PMID:23262942

  8. Coelho KE, et al. Misoprostol embryotoxicity: clinical evaluation of fifteen patients with arthrogryposis. Am J Med Genet. 2000. PMID: 11186880D

  9. Dabash R, et al. A double-blind randomized controlled trial of mifepristone or placebo before buccal misoprostol for abortion at 14-21 weeks of pregnancy. Int J Gynaecol Obstet 2015. PMID: 25896965

  10. Davis A, et al. Bleeding patterns after early abortion with mifepristone and misoprostol or manual vacuum aspiration. Am Med Womens Assoc 2000.

  11. Dickinson JE, et al. Mifepristone and oral, vaginal, or sublingual misoprostol for second-trimester abortion: a randomized controlled trial. Obstet Gynecol 2014. PMID: 24807339

  12. Fiala C, et al. Verifying the effectiveness of medical abortion; ultrasound versus hCG testing. Eur J Obstet Gynecol Reprod Biol. 2003. PMID: 12860340

  13. Fjerstad M, et al. Rates of serious infection after changes in regimens for medical abortion. NEJM. 2009. PMID: 19587339

  14. Friedlander EB, et al. Prophylactic Pregabalin to Decrease Pain During Medication Abortion: A Randomized Controlled Trial. Obstet Gynecol. 2018. PMID: 30095762

  15. Gatter M, et al. Efficacy and safety of medical abortion using mifepristone and buccal misoprostol through 63 days. Contraception. 2015. PMID: 25592080

  16. Guttmacher Institute, An Overview of Abortion Laws May 2019 https://www.guttmacher.org/state-policy/explore/overview-abortion-laws

  17. Guttmacher Institute, Report on State Abortion Policy https://www.guttmacher.org/gpr/2019/05/improving-access-abortion-telehealth

  18. Hollenbach SJ, et al. “Provoked” feto-maternal hemorrhage may represent insensible cell exchange in pregnancies from 6 to 22 weeks gestational age” Contraception. 2019. https://www.contraceptionjournal.org/article/S0010-7824(19)30129-5/fulltext

  19. Guest J, et al. Randomized controlled trial comparing the efficacy of same-day administration of mifepristone and misoprostol for termination of pregnancy with the standard 36 to 48-hour protocol. BJOG. 2007. PMID: 17305893K

  20. Kapp N, et al. Medical abortion in the late first trimester: a systematic review. Contraception 2019. PMID: 30444970

  21. Livshits A, et al. Ibuprofen and paracetamol for pain relief during medical abortion: A double-blind randomized controlled study. Fertility and sterility. 2009. PMID:18359021

  22. Mark A, et al. Foregoing Rh testing and anti-D immunoglobulin for women presenting for early abortion: a recommendation from NAF’s Clinical Policies Committee. Contraception 2019. PMID: 30867121

  23. National Abortion Federation, Clinical Practice Guidelines https://prochoice.org/resources/clinical-policy-guidelines/

  24. Sheldon WR et al. Early abortion with buccal versus sublingual misoprostol alone: a multicenter, randomized trial. Contraception 2019 PMID:30831103

  25. Raymond EG, et al. Prophylactic compared with therapeutic ibuprofen analgesia in first-trimester medical abortion: a randomized controlled trial. Obstet Gynecol. 2013. PMID:23921857.

  26. Raymond EG, et al. Sixteen Years of Overregulation: Time to Unburden Mifeprex. Mifeprex REMS Study Group. NEJM 2017. PMID: 28225670

  27. Raymond EG, et al. Serial multilevel urine pregnancy testing to assess medical abortion outcome: a meta-analysis. Contraception. 2017. PMID: 28041991

  28. Raymond EG, et al. Simplified medical abortion screening: a demonstration project. Contraception 2018. PMID: 29170088

  29. Raymond EG, et al. Efficacy of Misoprostol Alone for First-Trimester Medical Abortion: A Systematic Review. Obstet Gynecol 2019. PMID: 3053156

  30. Schreiber CA, et al. Mifepristone Pretreatment for the Medical Management of Early Pregnancy Loss. NEJM. 2018. PMID: 29874535

  31. Society of Family Planning Clinical Guideline. Medical management of first-trimester abortion. Contraception 2014. http://goo.gl/BJiETT

  32. Society of Family Planning Clinical Guidelines https://www.societyfp.org/resources/clinical-guidelines

  33. Upadhyay UD, et al. Incidence of emergency department visits and complications after abortion. Obstet Gynecol 2015. PMID: 25560122

Disclosures & Acknowledgements

It is the policy of the University of California Schools of Medicine to ensure balance, independence, objectivity and scientific rigor. All persons involved in the selection, development and presentation of content are required to disclose any real or apparent conflicts of interest.

Disclosures: None of the following faculty, project staff or reviewers have any financial relationships with commercial interests relevant to the content of this activity.

Funding: Society of Family Planning Research Fund

Faculty:

  • Eleanor Bimla Schwarz, MD, MS, Course Director Professor of Medicine, University of California, Davis

  • Mindy Sobota, MD, MS, MPhil Associate Professor of Medicine, Clinician Educator, Brown University

  • Suzan Goodman, MD, MPH Associate Clinical Professor of Family and Community Medicine, UCSF; TEACH Program Curriculum Director; UCSF Bixby Center for Global Reproductive Health

Clinical Reviewers:

  • Jessica Beaman, MD, MPH, Assistant Professor of Medicine, UC San Francisco

  • Courtney Benedict, CNM, MSN, Associate Director Medical Standards Implementation
    Planned Parenthood Federation of America

  • Rachel S. Casas, MD, EdM, Assistant Professor of Medicine; Penn State College of Medicine

  • Cynthia H. Chuang, MD, MSc, Chief, Division of General Internal Medicine
    Professor of Medicine and Public Health Sciences, Penn State College of Medicine

  • Daniel Grossman, MD, Professor, Department of Obstetrics, Gynecology & Reproductive Sciences; Director, Advancing New Standards in Reproductive Health (ANSIRH), UC San Francisco

  • Ivonne McLean, MD, Faculty Attending, Community Family Health Center, New York; Reproductive Health Access Project (RHAP) Provider

  • Christine Prifti, MD, Instructor of Medicine, Boston University School of Medicine

Web Development: Nitid Bit, LLC

Video Producer/Editor: Luke Walden

Director of Photography: Charlotte Hornsby

Sound Recordist: Alistair Farrant

Acting: Julia Register

Off-Label Disclosure: This educational activity contains discussion of unlabeled uses of agents that are not approved by the FDA. Please consult the prescribing information for each product.

Cultural Competency: This activity complies with California Assembly Bill 1195 which requires CME courses with patient care components to include curriculum addressing cultural and linguistic competencies.
The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views of the University of California, Brown University, or the Society of Family Planning.

References:

  1. Abbas D, et al. Outpatient medical abortion is safe and effective through 70 days gestation. Contraception. 2015. PMID: 26118638

  2. Achilles SL, et al. Prevention of infection after induced abortion: SFP guideline 20102. Society of Family Planning. Contraception. 2011. PMID: 21397086

  3. Aldrich T, et al. Does methotrexate confer a significant advantage over misoprostol alone for early medical abortion? A retrospective analysis of 8678 abortions. BJOG. 2007. PMID: 17439563

  4. Bearak JM, et al. Disparities and change over time in distance women would need to travel to have an abortion in the USA: a spatial analysis. Lancet Public Health. 2017. PMID: 29253373

  5. Chen AY, et al. Bleeding after medication-induced termination of pregnancy with two dosing schedules of mifepristone and misoprostol. Contraception. 2006 PMID:16531178

  6. Chen MJ, et al. Mifepristone With Buccal Misoprostol for Medical Abortion: A Systematic Review. Obstet Gynecol 2015. PMID: 26241251 https://escholarship.org/uc/item/0v4749ss

  7. Cleland K, et al. Significant adverse events and outcomes after medical abortion. Obstet Gynecol. 2013. PMID:23262942

  8. Coelho KE, et al. Misoprostol embryotoxicity: clinical evaluation of fifteen patients with arthrogryposis. Am J Med Genet. 2000. PMID: 11186880D

  9. Dabash R, et al. A double-blind randomized controlled trial of mifepristone or placebo before buccal misoprostol for abortion at 14-21 weeks of pregnancy. Int J Gynaecol Obstet 2015. PMID: 25896965

  10. Davis A, et al. Bleeding patterns after early abortion with mifepristone and misoprostol or manual vacuum aspiration. Am Med Womens Assoc 2000.

  11. Dickinson JE, et al. Mifepristone and oral, vaginal, or sublingual misoprostol for second-trimester abortion: a randomized controlled trial. Obstet Gynecol 2014. PMID: 24807339

  12. Fiala C, et al. Verifying the effectiveness of medical abortion; ultrasound versus hCG testing. Eur J Obstet Gynecol Reprod Biol. 2003. PMID: 12860340

  13. Fjerstad M, et al. Rates of serious infection after changes in regimens for medical abortion. NEJM. 2009. PMID: 19587339

  14. Friedlander EB, et al. Prophylactic Pregabalin to Decrease Pain During Medication Abortion: A Randomized Controlled Trial. Obstet Gynecol. 2018. PMID: 30095762

  15. Gatter M, et al. Efficacy and safety of medical abortion using mifepristone and buccal misoprostol through 63 days. Contraception. 2015. PMID: 25592080

  16. Guttmacher Institute, An Overview of Abortion Laws May 2019 https://www.guttmacher.org/state-policy/explore/overview-abortion-laws

  17. Guttmacher Institute, Report on State Abortion Policy https://www.guttmacher.org/gpr/2019/05/improving-access-abortion-telehealth

  18. Hollenbach SJ, et al. “Provoked” feto-maternal hemorrhage may represent insensible cell exchange in pregnancies from 6 to 22 weeks gestational age” Contraception. 2019. https://www.contraceptionjournal.org/article/S0010-7824(19)30129-5/fulltext

  19. Guest J, et al. Randomized controlled trial comparing the efficacy of same-day administration of mifepristone and misoprostol for termination of pregnancy with the standard 36 to 48-hour protocol. BJOG. 2007. PMID: 17305893K

  20. Kapp N, et al. Medical abortion in the late first trimester: a systematic review. Contraception 2019. PMID: 30444970

  21. Livshits A, et al. Ibuprofen and paracetamol for pain relief during medical abortion: A double-blind randomized controlled study. Fertility and sterility. 2009. PMID:18359021

  22. Mark A, et al. Foregoing Rh testing and anti-D immunoglobulin for women presenting for early abortion: a recommendation from NAF’s Clinical Policies Committee. Contraception 2019. PMID: 30867121

  23. National Abortion Federation, Clinical Practice Guidelines https://prochoice.org/resources/clinical-policy-guidelines/

  24. Sheldon WR et al. Early abortion with buccal versus sublingual misoprostol alone: a multicenter, randomized trial. Contraception 2019 PMID:30831103

  25. Raymond EG, et al. Prophylactic compared with therapeutic ibuprofen analgesia in first-trimester medical abortion: a randomized controlled trial. Obstet Gynecol. 2013. PMID:23921857.

  26. Raymond EG, et al. Sixteen Years of Overregulation: Time to Unburden Mifeprex. Mifeprex REMS Study Group. NEJM 2017. PMID: 28225670

  27. Raymond EG, et al. Serial multilevel urine pregnancy testing to assess medical abortion outcome: a meta-analysis. Contraception. 2017. PMID: 28041991

  28. Raymond EG, et al. Simplified medical abortion screening: a demonstration project. Contraception 2018. PMID: 29170088

  29. Raymond EG, et al. Efficacy of Misoprostol Alone for First-Trimester Medical Abortion: A Systematic Review. Obstet Gynecol 2019. PMID: 3053156

  30. Schreiber CA, et al. Mifepristone Pretreatment for the Medical Management of Early Pregnancy Loss. NEJM. 2018. PMID: 29874535

  31. Society of Family Planning Clinical Guideline. Medical management of first-trimester abortion. Contraception 2014. http://goo.gl/BJiETT

  32. Society of Family Planning Clinical Guidelines https://www.societyfp.org/resources/clinical-guidelines

  33. Upadhyay UD, et al. Incidence of emergency department visits and complications after abortion. Obstet Gynecol 2015. PMID: 25560122

TEACH cultivates the next generation of diverse reproductive health champions through abortion training, mentorship and curriculum development.

335 S. Van Ness Ave.
San Francisco, CA 94103

(415) 500-8122

TEACH is fiscally sponsored by Social and Environmental Entrepreneurs, a 501(c)3 non-profit organization that supports small organizations like ours.

TIN: 95-4116679

© 2024 TEACH. All rights reserved.

Website by lover studio

TEACH cultivates the next generation of diverse reproductive health champions through abortion training, mentorship and curriculum development.

335 S. Van Ness Ave.
San Francisco, CA 94103

(415) 500-8122

TEACH is fiscally sponsored by Social and Environmental Entrepreneurs, a 501(c)3 non-profit organization that supports small organizations like ours.

TIN: 95-4116679

© 2024 TEACH. All rights reserved.

Website by lover studio

TEACH cultivates the next generation of diverse reproductive health champions through abortion training, mentorship and curriculum development.

335 S. Van Ness Ave.
San Francisco, CA 94103

(415) 500-8122

TEACH is fiscally sponsored by Social and Environmental Entrepreneurs, a 501(c)3 non-profit organization that supports small organizations like ours.

TIN: 95-4116679

© 2024 TEACH. All rights reserved.

Website by lover studio

TEACH cultivates the next generation of diverse reproductive health champions through abortion training, mentorship and curriculum development.

335 S. Van Ness Ave.
San Francisco, CA 94103

(415) 500-8122

TEACH is fiscally sponsored by Social and Environmental Entrepreneurs, a 501(c)3 non-profit organization that supports small organizations like ours.

TIN: 95-4116679

© 2024 TEACH. All rights reserved.

Website by lover studio